- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04222062
A Study Comparing GLIADEL to Stereotactic Radiosurgery in Metastatic Brain Disease
A Randomized Trial Evaluating GLIADEL Compared to Stereotactic Radiosurgery in Subjects With Metastatic Brain Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is being done to assess the efficacy of GLIADEL (a local chemotherapy) in preventing local recurrence of a metastatic brain tumor compared to stereotactic radiosurgery (SRS) after resection.
100 Adult subjects with one to four metastatic brain tumors with one tumor needing resection will be enrolled. Subjects with prior radiation, lymphoma, small cell, germ cell, unknown primary, or anaplastic thyroid diagnoses will be ineligible. Life expectancy should be greater than 3 months.
Subjects will be randomized at the time of surgery to 1) GLIADEL placement at the time of resection or 2) SRS post-operatively to the resection cavity. Any other tumors (up to three) will have SRS as their primary treatment after surgery. SRS will take place within 6 weeks from surgery.
Subjects will be evaluated pre-operatively with MRI brain and neuropsychological testing and will have immediate post-op MRI for extent of resection (EOR) determination. Subjects will have SRS to the resection cavity if no GLIADEL was placed and all will have SRS to any other lesions. They will be followed at set intervals to evaluate for local recurrence and neurocognitive changes. The genome of the metastatic brain tumor will be compared to their primary and germline for identification of alterations.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Taylor A Johnson, BS, MA
- Phone Number: 402-559-4596
- Email: taylora.johnson@unmc.edu
Study Contact Backup
- Name: Erin E Rogers
- Phone Number: 402-559-0963
- Email: errogers@unmc.edu
Study Locations
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Not yet recruiting
- Henry Ford
-
Principal Investigator:
- Ian Lee, MD
-
-
Nebraska
-
Omaha, Nebraska, United States, 68198
- Recruiting
- University of Nebraska Medical Center
-
Contact:
- Michele R Aizenberg Ansari, MD
- Phone Number: 402-559-9614
- Email: maizenberg@unmc.edu
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Not yet recruiting
- Ohio State University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18 years or older (Nebraska is 19 years or older)
- Karnofsky Performance Score ≥ 70
- RPA class I or II
- Known or suspected primary solid cancer with metastatic brain tumor(s) - up to four in number and up to 4 cm in size with surgical resection planned for one or two tumors.
- Adequate platelet count (≥ 100,000/mm3), transfusion permitted
- Laboratory values adequate for patient to undergo surgery, including: (transfusion permitted to reach goals)
- Women of childbearing potential must have a negative pregnancy test within 7 days of initiating study
- INR ≤ 1.3
- Estimated survival time of ≥ 3 months as determined by the patient's primary oncologist.
- The subject is willing and able to consent to and abide by the protocol.
Exclusion Criteria:
- Prior treatment to the area of planned resection (surgery, radiation).
- Prior whole brain radiation therapy.
- Diagnosis of lymphoma, germ cell cancer, small cell lung cancer, anaplastic thyroid cancer.
- Leptomeningeal disease
- Neurodegenerative disorder (e.g. dementia).
- Tumor size > 4 cm.
- RPA class III
- Inability or unwillingness to co-operate with the requirements of the protocol
- Any other clinically significant medical disease or condition laboratory abnormality or psychiatric illness that, in the Investigator's opinion, may interfere with protocol adherence or confound efficacy or safety assessment or a subject's ability to give informed consent.
- Participation in other therapeutic clinical trials
Severe pulmonary, cardiac or other systemic disease, specifically:
- New York Heart Association > Grade 2 congestive heart failure within 6 months prior to study entry, unless asymptomatic and well controlled with medication
- Uncontrolled or significant cardiovascular disease, clinically significant ventricular arrhythmia, clinically significant pulmonary disease
- Subjects who have any other disease, either metabolic or psychological, which as per the Investigator assessment may affect the subject's compliance or place the subject at higher risk of potential treatment complications.
- The subject has a bleeding diathesis, or must take anticoagulants, or antiplatelet agents including NSAIDs (non-steroidal anti-inflammatory drugs), at the time of scheduled resection that cannot be stopped for surgery.
- Inability to obtain MRI studies.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Standard of Care Arm
The tumor will be removed surgically.
Within 6 weeks after surgery, the resection will be treated with stereotactic radiosurgery (SRS).
|
|
Experimental: GLIADEL Arm
Once the tumor has been removed, GLIADEL wafers will be applied to the resection cavity.
The number of wafers used will be determined by the size of the cavity.
Enough wafers should be used so that as much of the cavity is covered as possible.
|
GLIADEL wafers will be placed to cover tumor bed immediately after tumor removal.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy of GLIADEL compared to Stereotactic Radiosurgery (SRS)
Time Frame: 12 months
|
The primary outcome is to evaluate the efficacy of GLIADEL local chemotherapy compared to Stereotactic Radiosurgery (SRS) in preventing local recurrence after resection of a metastatic brain tumor (local recurrence at surgical site).
|
12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Michele Aizenberg, MD, University of Nebraska
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0792-19-FB
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain Tumor - Metastatic
-
University of Erlangen-Nürnberg Medical SchoolNot yet recruitingBrain Tumor, Primary | Brain Tumor - MetastaticGermany
-
University of NebraskaRecruitingPrimary Brain Tumor | Metastatic Brain TumorUnited States
-
Pietro Mortini, MD, Prof.RecruitingBrain Tumor, Primary | Brain Tumor - MetastaticItaly
-
Swedish Medical CenterUnknownMetastatic Brain TumorUnited States
-
Memorial Sloan Kettering Cancer CenterAstraZenecaRecruitingSolid Tumor | Metastatic Cancer | Metastatic Solid Tumor | Solid Tumor, Adult | Solid Carcinoma | Metastatic TumorUnited States
-
Royal Marsden NHS Foundation TrustNational Institute for Health Research, United KingdomCompletedBone Metastases | Brain Metastases | Brain Tumor, Primary | Brain Tumor Adult | Brain Tumor - MetastaticUnited Kingdom
-
Memorial Sloan Kettering Cancer CenterRecruitingBrain Tumor | Metastatic Brain TumorUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI); Eisai Inc.CompletedPrimary Brain Tumor | Metastatic Malignant Neoplasm in the Adult BrainUnited States
-
Albert Einstein College of MedicineTerminatedCancer | Solid Tumor | Metastatic Solid Tumor | Metastatic dMMR Solid CancerUnited States
-
GT Medical Technologies, Inc.RecruitingBrain Tumor | Brain Tumor, Recurrent | Brain Tumor, Primary | Brain Tumor - Metastatic | Brain Tumor, Adult: Glioblastoma | Brain Tumor, Adult MeningiomaUnited States
Clinical Trials on Carmustine 7.7Mg Wafer
-
INSYS Therapeutics IncCompletedGlioblastoma MultiformeUnited States, Canada, United Kingdom, Germany, Israel, Netherlands
-
University of IowaEisai Inc.TerminatedPrimary Glioblastoma MultiformeUnited States
-
Kentuckiana Cancer InstituteEisai Inc.UnknownNewly Diagnosed Supratentorial Malignant GliomaUnited States
-
Duke UniversityNational Cancer Institute (NCI)CompletedRecurrent Adult Brain TumorUnited States
-
Methodist HealthcareTerminatedGlioblastoma Multiforme | High-Grade GliomaUnited States
-
Fraser Orthopaedic Research SocietyTerminated
-
Everfront Biotech Co., Ltd.Active, not recruitingRecurrent High Grade GliomaTaiwan
-
The Hong Kong Polytechnic UniversityThe Hong Kong Jockey Club Charities TrustCompleted
-
Armed Forces Institute of Dentistry, PakistanCompletedAnalgesia | Orthodontic Appliance ComplicationPakistan